Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

For children ages 12 to 17, an adult should supervise the shots. Dupixent's list of uses already includes asthma, eczema, chronic sinus inflammation with nasal polyps, eosinophilic food pipe ...

The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema. Analysts predict peak annual ...

Sanofi and partner Regeneron have picked up an approval in Europe for Dupixent in asthma, unlocking an important new indication for the fast-growing biologic. Dupixent (dupilumab) – an ...

Prescribers currently state that Sanofi/Regeneron’s Dupixent continues to lead current adult biologic brand share. Despite the widespread use of biologics for the treatment of asthma ...

Sales of its blockbuster asthma drug Dupixent rose 20.3% to 3.48 billion euros, compared with 3.44 billion euros expected on average by analysts. Sales of Beyfortus, a new treatment to protect ...

such as atopic dermatitis and asthma — providing patients with one treatment that might help multiple atopy conditions.” Approval of (Dupixent, Regeneron/Sanofi) was based on data from two ...